Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Aquestive Therapeutics (NASDAQ: AQST) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, a virtual event on February 25-26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aquestive Therapeutics (NASDAQ: AQST) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, a virtual event on February 25-26, 2026. Management will present on February 26 at 12:00 PM ET and will hold investor one-on-ones the same day.
A webcast will be available on the company’s Investors "Events and Presentations" page, with a replay accessible for 30 days following the presentation.
Details
News Market Reaction – AQST
On Feb 23, the day this news came out, AQST closed 0.51% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
Key Figures
- Conference dates
- February 25–26, 2026
- Oppenheimer 36th Annual Healthcare Life Sciences Conference
- Company presentation time
- 12:00 p.m. ET
- Aquestive presentation on February 26, 2026
- Webcast replay period
- 30 days
- Replay availability after the conference presentation
Historical Context
-
Planned presentation of new Anaphylm clinical data at AAAAI meeting.
-
Appointment of award‑winning allergist as Chief Medical Officer.
-
FDA Complete Response Letter for Anaphylm focused on packaging and PK study.
-
FDA identified deficiencies in Anaphylm NDA ahead of Jan 31, 2026 PDUFA date.
-
Participation in Piper Sandler conference with Anaphylm-focused fireside chat.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WARREN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, which is a virtual event.
The Aquestive team will be presenting on February 26th, at 12 pm ET; management will also be hosting one-on-ones with investors that same day.
A webcast of the presentation will be available under the “Events and Presentations” page of the Investors section of the Company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
About Aquestive Therapeutics, Inc.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. The worldwide leader in delivering trusted, quality medications on oral film, Aquestive operates as both a developer of its own proprietary products and a Contract Development and Manufacturing Organization (CDMO) for licensees, with its headquarters in New Jersey and U.S.-based manufacturing facilities in Indiana. The Company is the exclusive manufacturer of four commercialized products marketed by its licensees across six continents using proprietary, best-in-class technologies like PharmFilm®. Aquestive's AdrenaVerse™ platform contains a library of more than 20 epinephrine prodrugs enabling the pursuit of various potential allergy and dermatological indications. The Company is advancing Anaphylm™ (dibutepinephrine) sublingual film for the treatment of severe allergic reactions, including anaphylaxis, and AQST-108 (epinephrine prodrug) topical gel for various potential dermatological conditions, including alopecia areata. For more information, visit Aquestive.com and follow us on LinkedIn.
Forward Looking Statement
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of its product development activities and clinical trials, including relating to Anaphylm™ (dibutepinephrine) sublingual film, and other risks and uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the U.S. Securities and Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.
PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc.
Investor Contact:
Brian Korb
astr partners
brian.korb@astrpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.